LAVA Therapeutics NV
NASDAQ:LVTX
LAVA Therapeutics NV
NASDAQ:LVTX
Price:
1.18
USD
-7.09%
Market Closed
Market Cap:
31m
USD
LAVA Therapeutics NV
Cash from Financing Activities
|
LAVA Therapeutics NV
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Cash from Financing Activities
-$571k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Cash from Financing Activities
-$34.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Cash from Financing Activities
€70.3m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-5%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Cash from Financing Activities
-$59.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
argenx SE
XBRU:ARGX
|
Cash from Financing Activities
$1.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Cash from Financing Activities
$494m
|
CAGR 3-Years
21%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
LVTX
Intrinsic Value
1.96
USD
Undervaluation 40%
See Also
What is LAVA Therapeutics NV's Cash from Financing Activities?
Cash from Financing Activities
-571k
USD
-571k
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Cash from Financing Activities amounts to -571k USD.
You don't have any saved screeners yet